November 23, 2020 By Grow Opportunity staff
Canopy Growth Corp.’s medical division, Spectrum Therapeutics, has published a new study on the long-term effects of cannabidiol, or CBD.
According to this study, CBD did not demonstrate any degree of acute or lifelong toxicity or related liabilities at physiological concentrations. Instead, data suggests that CBD could extend mean lifespan up to 18 per cent and increase late-stage life activity by up to 206 per cent compared to untreated controls within the study.
“Despite widespread use of CBD, no lifelong toxicity studies had been conducted to date to determine the impact – or potential impact – of long-term exposure to CBD,” said Hunter Land, senior director of Translational and Discovery Science at Canopy Growth. “These results serve as the only CBD life-long exposure data in an in vivo model to date, and the absence of long-term toxicity gives us the evidence we need as an industry to continue researching the potential health benefits for the broader application of CBD.”
The study represents one of the first research projects looking at the long-term toxicity and lifespan effects of CBD in the preclinical model, Caenorhabditis elegans. It was commissioned as part of the company’s move to provide research data to support and influence public policy.
The study was conducted in partnership with NemaLife Inc. and is published in Cannabis and Cannabinoid Research journal.
Print this page